Literature DB >> 16896900

[Dynamic graciloplasty vs artificial bowel sphincter in the management of severe fecal incontinence].

O Ruthmann1, A Fischer, U T Hopt, H J Schrag.   

Abstract

Dynamic graciloplasty (DGP) and the Acticon Neosphincter (artificial bowel sphincter, ABS) are well-established therapeutic instruments in patients with severe fecal incontinence. However, the success rates in the literature must be interpreted with caution. The report presented here presents firstly a critical analysis of 1510 patients in 52 studies (29 DGP vs 23 ABS). The evidence of these studies was assessed using the Oxford EBM criteria. All data were statistically analysed. Up to 94% of the studies analysed show EBM levels of only >3b. Both procedures show significant improvements in postoperative continence scores (p<0.001) and a significant advantage of ABS over DGP. Nevertheless, they are associated with a high incidence of morbidity in the long term (infection rate ABS vs DGP 21.74% vs 35.1%, revision rate ABS vs DGP 37.53% vs 40.64%, and ABS explantation rates of 30%). Presently no therapeutic recommendation can be expressed based on the few data available. Furthermore, therapy should be performed in specialized centers and patients should be given a realistic picture of the critical outcome of both surgical techniques.

Entities:  

Mesh:

Year:  2006        PMID: 16896900     DOI: 10.1007/s00104-006-1217-0

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  70 in total

1.  Morbidity and functional outcome after double dynamic graciloplasty for anorectal reconstruction.

Authors:  E Rullier; F Zerbib; C Laurent; M Caudry; J Saric
Journal:  Br J Surg       Date:  2000-07       Impact factor: 6.939

2.  Long-term results of modified graciloplasty for sphincter replacement after rectal excision.

Authors:  H. R Rosen; C Urbarz; G Novi; G Zöch; R Schiessel
Journal:  Colorectal Dis       Date:  2002-07       Impact factor: 3.788

3.  Preliminary results of a multicentre trial of the electrically stimulated gracilis neoanal sphincter.

Authors:  B J Mander; S D Wexner; N S Williams; D C Bartolo; D Z Lubowski; T Oresland; G Romano; M R Keighley
Journal:  Br J Surg       Date:  1999-12       Impact factor: 6.939

4.  Treatment of anal incontinence by an implantable prosthetic anal sphincter.

Authors:  J Christiansen; B Sparsø
Journal:  Ann Surg       Date:  1992-04       Impact factor: 12.969

5.  Development of an electrically stimulated neoanal sphincter.

Authors:  N S Williams; J Patel; B D George; R I Hallan; E S Watkins
Journal:  Lancet       Date:  1991-11-09       Impact factor: 79.321

6.  Rectal sphincter reconstruction using gracilis muscle transplant.

Authors:  K PICKRELL; F MASTERS; N GEORGIADE; C HORTON
Journal:  Plast Reconstr Surg (1946)       Date:  1954-01

7.  Use of the gracilis muscles for sphincteric construction after abdominoperineal resection. Technique and preliminary results.

Authors:  U Mercati; V Trancanelli; G P Castagnoli; A Mariotti; R Ciaccarini
Journal:  Dis Colon Rectum       Date:  1991-12       Impact factor: 4.585

8.  Artificial anal sphincter: prospective clinical and manometric evaluation.

Authors:  P A Lehur; J V Roig; M Duinslaeger
Journal:  Dis Colon Rectum       Date:  2000-08       Impact factor: 4.585

9.  Long-term follow-up of dynamic graciloplasty for faecal incontinence.

Authors:  M J Thornton; M L Kennedy; D Z Lubowski; D W King
Journal:  Colorectal Dis       Date:  2004-11       Impact factor: 3.788

10.  Dynamic graciloplasty in patients born with an anorectal malformation.

Authors:  Sacha M Koch; Ozenç Uludağ; Mart-Jan Rongen; Cor G Baeten; Wim van Gemert
Journal:  Dis Colon Rectum       Date:  2004-10       Impact factor: 4.585

View more
  1 in total

1.  Dynamic versus Adynamic Graciloplasty in Treatment of End-Stage Fecal Incontinence: Is the Implantation of the Pacemaker Really Necessary? 12-Month Follow-Up in a Clinical, Physiological, and Functional Study.

Authors:  Piotr Walega; Michal Romaniszyn; Benita Siarkiewicz; Dorota Zelazny
Journal:  Gastroenterol Res Pract       Date:  2015-03-11       Impact factor: 2.260

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.